Lido Advisors LLC Cuts Stock Position in Lantheus Holdings, Inc. $LNTH

Lido Advisors LLC lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 62,205 shares of the medical equipment provider’s stock after selling 4,953 shares during the quarter. Lido Advisors LLC’s holdings in Lantheus were worth $4,140,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Hantz Financial Services Inc. raised its stake in shares of Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 396 shares during the period. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus in the 2nd quarter valued at $36,000. Farther Finance Advisors LLC raised its stake in shares of Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 275 shares during the period. Larson Financial Group LLC raised its stake in shares of Lantheus by 324.5% in the 4th quarter. Larson Financial Group LLC now owns 658 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 503 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Lantheus in the 3rd quarter valued at $55,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on LNTH shares. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th. Finally, William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Stock Performance

Lantheus stock opened at $100.98 on Friday. The firm’s fifty day moving average price is $88.01 and its 200 day moving average price is $74.96. The company has a market capitalization of $6.57 billion, a price-to-earnings ratio of 24.33 and a beta of -0.03. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $104.00. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts forecast that Lantheus Holdings, Inc. will post 4.42 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.